Ensysce Biosciences, Inc.

What they do

Ensysce develops abuse-resistant and overdose-protected opioid pain drugs using its TAAP (trypsin-activated abuse protection) and MPAR (Multi-Pill Abuse Resistance) platforms. Its lead candidate, PF614, is a TAAP oxycodone prodrug that remains inactive until swallowed, designed to deter non-oral abuse. PF614-MPAR adds overdose protection by switching off opioid release when supratherapeutic doses are taken. The company has no approved products and no product-sale revenue; reported revenue comes from grants and collaboration agreements.

Revenue drivers

• Grant Revenue — Revenue primarily from government and foundation grants, contributing $5.1M in 2025 and $961K in Q1 2026.
• Research Collaborations — Collaborative agreements providing milestone or service-based payments, though no product sales exist.
• No Commercial Products — No approved products; all candidates are in clinical or preclinical stages, generating no commercial revenue.

Recent performance

For Q1 2026, revenue was $960,999. The company reported a net loss of $10.2M for fiscal 2025, with an accumulated deficit and going concern doubt. Cash and equivalents totaled $745,482 as of March 31, 2026, with total assets of $2.2M and shareholders' deficit of $340,042. During Q1, Ensysce enrolled 50% of the interim target in its Phase 3 PF614-301 trial, published peer-reviewed data for PF614-MPAR, and expanded its patent estate. The board initiated a formal review of strategic alternatives.

Strategy

Management intends to advance PF614 through Phase 3 trials and PF614-MPAR through Phase 1b development, with the goal of regulatory approval via the 505(b)(2) pathway. The company is simultaneously expanding its intellectual property for both opioid and ADHD programs. It also plans to pursue partnerships or licensing deals to accelerate clinical and commercial progress, as reflected in the strategic alternatives review. Funding will continue from equity and debt offerings, grants, and potential collaborations.

Risks

• Going Concern Doubt — The company has substantial doubt about its ability to continue as a going concern due to no product revenue, recurring losses, and reliance on external financing.
• Clinical-Stage with No Approved Products — Ensysce has never obtained regulatory approval, manufactured at commercial scale, or generated product revenue, and may never succeed in doing so.
• Heavy Dependence on PF614 — The business is almost entirely dependent on the success of PF614 and PF614-MPAR, which are still in clinical trials and may fail.
• Need for Substantial Additional Funding — With cash of $745K and significant ongoing R&D expenses, the company requires immediate additional capital to continue operations and trials.

Outlook

Management expects to report interim data from the PF614-301 Phase 3 trial later in 2026 and to initiate Part 3 of the PF614-MPAR-102 study. The formal strategic alternatives review may lead to partnerships, licensing, or other transactions. The company acknowledges it will continue to incur net losses for the foreseeable future and needs substantial additional funding to execute its plans.